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Abstract
Laser interstitial thermal therapy (LITT) is a novel minimally invasive
neurosurgical procedure in which laser light is delivered through a stereotactically
positioned probe to an intracranial lesion for controlled thermal ablation of the
pathological tissue. LITT is considered for patients who are poor candidates for
open surgical resection due to (1) location of lesion (e.g., deep-seated or near
critical structures), (2) history of intracranial interventions or medical
comorbidities that increase surgical risk, or (3) lesion refractoriness to prior
conventional therapies. The use of LITT was initially limited by concerns over
off-target thermal damage; however, recent advances in magnetic resonance
imaging-based thermal imaging have enabled real-time monitoring of tissue
ablation dynamics, thereby improving its safety profile. Accordingly, the past two
decades have seen a rapid expansion in the use of LITT for a variety of intracranial
pathologies, including neoplasms, radiation necrosis, and epilepsy. This chapter
focuses on the novel application of LITT to both newly diagnosed and recurrent
glioblastoma multiforme (GBM). We first review the technological developments
that enabled the safe use of LITT for GBM. We then review recent evidence
regarding the indications, outcomes, and limitations of LITT as a novel adjuvant
treatment for GBM.
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1. Introduction
1.1 Glioblastoma multiforme: standard-of-care and prognosis
World Health Organization (WHO) grade IV glioma (glioblastoma multiforme)
is the most common and most lethal malignant primary brain tumor. The incidence
in the United States is estimated to be 3.12 per 100,000 persons with a median age
of 64 years at diagnosis [1]. Current standard-of-care guidelines for initial
treatment for grade III or IV gliomas (high-grade gliomas (HGG)) are maximal safe
surgical resection followed by adjuvant temozolomide chemotherapy and radiation
[2]. Although standard-of-care treatment improves median survival from 3 months
in untreated patients to 14.8 months, GBM remains a terminal diagnosis as tumors
inevitably recur [2, 3]. There are few positive prognostic factors. In a minority of
patients, certain tumor molecular phenotypes correlate with improved prognosis.
For example, methylguanine methyltransferase (MGMT) promoter
hypermethylation is associated with an increased median survival of 21.7 months.
Isocitrate dehydrogenase 1 (IDH) mutation-positive tumors, especially in
1
combination with MGMT hypermethylation, also correlate with a survival benefit
[4]. Other favorable prognostic factors include younger age at diagnosis, pre-
treatment functional status, and extent of surgical resection of the tumor mass [5].
1.2 Rationale for use of LITT for glioblastoma
Recent studies have improved our understanding of how the extent of surgical
resection impacts progression-free survival and overall survival for GBM patients
[6, 7]. Although GBM is a diffusely infiltrative disease, gross total resection (GTR)
is associated with increased progression-free survival and overall survival compared
to subtotal resection (STR), which itself confers a survival benefit compared to
biopsy alone [7]. Studies aiming to quantify a threshold extent of resection have
concluded that a threshold at 78% resection of radiographic tumor is necessary to
confer a survival benefit compared to radiation and chemotherapy alone [8–11].
Other recent studies have found an additional survival benefit from supra-total
resection (i.e., resection beyond the contrast-enhancing tumor margins) to include
any fluid-attenuated inversion recovery (FLAIR) abnormalities or a total right
frontal or parietal lobectomy compared to GTR [12, 13]. These findings support the
current standard-of-care guidelines for maximal safe surgical resection and rein-
force the primary role of cytoreduction in GBM treatment.
However, some patients may not be able to undergo conventional open surgical
resection. Factors contributing to this include medical comorbidities that increase
surgical risk, low preoperative functional status, inability to tolerate general anes-
thesia, and history of radiation therapy or prior craniotomy that may impair wound
healing and increase risk of postoperative neurological worsening [14]. Up to 40%
of GBM tumors are considered surgically “unresectable” based on their location in
deep or eloquent brain regions or adjacent to critical neurovascular structures [15].
Postoperative neurological deficits from injury to eloquent brain regions during
open surgical resection are associated with reduced overall survival and functional
status [16]. When open surgery is not an option, patients may simply receive a
needle biopsy for diagnosis and chemoradiation. For these patients, laser interstitial
thermal therapy is a minimally invasive alternative approach for cytoreductive
intervention.
2. Laser interstitial thermal therapy: Principles and technological
developments
2.1 Technological principles
LITT is a minimally invasive neurosurgical procedure that delivers laser light to
an intracranial target to thermally ablate pathological tissue [17]. Laser light is a
form of non-ionizing radiation and is emitted from a power source as a coherent
beam of electromagnetic radiation. Laser light is delivered intracranially through a
fiber optic ensheathed in a rigid laser probe that can be stereotactically inserted
along a linear trajectory from a single skull entry point to the lesion. The primary
mechanism of thermal damage occurs when laser light is absorbed by tissue water
and hemoglobin molecules, causing excitation and release of heat. In LITT, laser
light in the near-infrared range (980–1064 nm) is used to maximize tissue
penetrance (up to 10 mm). Tissue heating to at least 43°C for several minutes is
sufficient to cause irreversible tissue damage; heating to 60°C rapidly induces
protein denaturation and damage to DNA and lipid membranes, resulting in
coagulative necrosis [18]. At 100°C, tissue vaporization occurs, which can result in
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increased intracranial pressure. Tissue charring at temperatures >90°C can also
damage healthy brain and impair laser penetration to further target regions.
Therefore, the ideal temperature range for thermal ablation is 50–90°C [19].
The first use of LITT in neurosurgery was reported in the early 1980s [20];
however, concerns were raised over how to limit thermal injury to pathological
tissue only [21]. Although early LITT users could stereotactically position a laser
optical fiber to the center of a lesion, they did not have an accurate method for
measuring heat distribution throughout the target and to surrounding off-target
areas. Two advances in LITT technology have improved its safety: (1) real-time
magnetic resonance (MR) thermometry and (2) the development of commercially
available LITT systems that successfully integrate MR thermometry data and
enhanced control over laser energy delivery into a standard workflow.
MR thermometry was introduced in the 1990s as a way to monitor real-time
changes in tissue temperature on an MR imaging sequence [22, 23]. T2-weighted
MRI images are taken intraoperatively; changes in tissue temperature affect the
water proton resonance frequency signal in a linear relationship and can be mapped
onto pixels of the MRI image. The result is a heat damage map that can be updated
throughout the procedure and used to guide the boundaries of laser ablation [24].
The NeuroBlate laser ablation system (Monteris, Inc.) and the Visualase
Thermal Therapy System (Medtronic, Inc.) received Food and Drug Administration
(FDA) approval in 2007 and 2009, respectively. These commercial LITT platforms
use MR thermometry software that allows the surgeon to define a maximum
temperature threshold at the periphery of the target lesion; surpassing this
threshold automatically triggers laser shutdown to protect off-target regions [24].
The Visualase and NeuroBlate LITT systems also improved procedure safety in
designing a cooling sheath to surround the laser fiber along the length of laser
probe, thereby limiting thermal damage to the tip of the probe [18].
2.2 Overview of the LITT setup and workflow
The LITT setup consists of four components: (1) laser energy source, (2) laser
applicator probe, (3) cooling mechanism, and (4) computer workstation with soft-
ware for processing real-time MRI thermometry data and controlling laser energy
delivery. The patient is induced under general anesthesia or monitored anesthesia
care (MAC). In the operating room, the laser trajectory from a skull entry point to the
target lesion is planned using standard neuronavigation (e.g., Stealth system,
Medtronic Inc.) technology. The laser applicator probe is stereotactically positioned
along this trajectory through a single burr hole at the entry point. The surgeon may
opt to perform stereotactic needle biopsy prior to implantation of the applicator
probe to obtain a histopathological diagnosis. The patient is then transferred to an
MRI suite under anesthesia. Laser energy is delivered through the probe to the target
lesion in controlled doses lasting several minutes each. Concurrent real-time MRI
thermal imaging (MRTI) of the treatment region allows the user to adjust laser output
parameters so that thermal ablation of the target is achieved while avoiding thermal
damage to normal surrounding brain tissue. Following LITT treatment, the applicator
probe is removed, and the small skin opening overlying the entry point is closed.
2.3 LITT system platforms and surgical technique
2.3.1 LITT system platforms
The NeuroBlate system consists of a 12-Watt (W) pulsed-output 1064 nm
wavelength neodymium-doped yttrium aluminum garnet (Nd-YAG) laser with a
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side-firing laser probe design, allowing some control over the direction of ablation.
Temperature at the tip is controlled with a C02 gas cooling mechanism with a built-
in thermocouple for feedback control. The Visualase system consists of a 15 W
980 nm diode laser with diffusing-tip probe design. Within the probe, the laser
fiber optic is ensheathed within catheter circulating cooled saline. Both systems
have a computer workstation with software for MR thermal imaging analysis and
control over laser treatment parameters [25]. The 1064 nm wavelength laser used in
the NeuroBlate system allows for deeper tissue penetration and potentially larger
ablation zone, while the Visualase 980 nm wavelength laser produces more efficient
heating [9].
2.3.2 Surgical procedure
After the patient is induced under anesthesia, stereotactic registration is
performed to plan laser probe trajectory. If a stereotactic headframe is used to set
the laser probe trajectory, then a preoperative T1-weighted MRI with contrast and
neuronavigation technology is used to plan the trajectory. If the surgeon is using a
frameless setup for registration, then an initial computed-tomography (CT) head
with fiducial markers is obtained; this is merged with preoperative T1-weighted
MRI with contrast studies, and then registration proceeds using neuronavigation.
Once registration is complete, a linear trajectory is planned connecting a single
entry site at the skull to the lesion that avoids critical brain structures. A trajectory
that is orthogonal to the skull surface in all three dimensional planes helps to
prevent skiving during drilling and catheter placement and should be utilized. After
image registration, the entry point is found with the navigation wand and marked.
Local anesthetic is infiltrated at the scalp over the entry site. A precision aiming
device and Stealth navigation wand are aligned along the planned trajectory.
A 4-mm incision is made to bring the navigation wand tip onto the skull surface
entry point. A small burr hole is made with a 3.2-mm drill bit. After the dura is
punctured, a reducing cannula is used to pass a rigid stylet, which maintains align-
ment during placement of the plastic bone anchor. The plastic bone anchor is
screwed into the skull with the rigid stylet as a guide. The laser probe is placed into
the cooling catheter and fixed in place (Figure 1). The patient is then transported
under sterile draping and with continued general anesthesia to the MRI suite, where
a T2-weighted MRI imaging is then performed to confirm placement of the laser
probe in the lesion.
The LITT system software is used to set maximum temperature thresholds of
90°C in the immediate ablation zone around the laser probe tip and 50°C at the
target periphery to ensure tissue ablation throughout the target zone
(Figure 2A–D). Additional maximum temperature thresholds are set in the normal
parenchyma surrounding the lesion that, if reached, trigger automatic shutoff to
avoid off-target tissue damage [19]. Under real-time MR thermography guidance, a
30–60-second, 3–4 W-test dose is administered to localize the distal end of the laser
probe. Once localization of the laser probe to the target is confirmed, the lesion is
treated with 10–15 W doses of laser light in 1–3 minute intervals. Ablation is
considered complete when the region of tissue reaching 50°C is covered
(Figure 2E). After ablation is complete, the LITT apparatus is removed through the
burr hole craniotomy, and the skin is closed. Typical length of hospital stay is under
48 hours [19, 24, 26, 27].
Postoperative MRI imaging is typically obtained on the first day following LITT.
On T1-weighted MRI with contrast, the thermal ablation zone has a thin enhancing
rim with potential surrounding edema and enhancing residual blood products and
protein coagulation [19]. Residual tumor remaining after subtotal ablation can be
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detected on this first postoperative scan. The extent of ablation can be determined
using volumetric analysis volume of the ablation zone postoperatively to the volume
of the lesion on the preoperative MRI obtained for surgical planning [28].
Figure 1.
Intraoperative setup for laser interstitial thermal therapy. The laser probe trajectory is planned under
neuronavigation. The skin overlying the skull entry point is incised, a small burr hole is drilled, and a small
incision in the dura is made. A cannula is inserted and used to guide the rigid stylet and bone anchor in the
correct orientation along the planned trajectory.
Figure 2.
Representative results of MR thermometry, which acquires real-time temperature data for each pixel of an M2-
weighted MRI image. Representative preoperative sagittal (A), axial (B), and coronal (C) T1-weighted MRI
with contrast images are suggestive of high-grade glioma. In planning a course of LITT, markers for temperature
thresholds to achieve ablation while avoiding off-target damage or tissue vaporization are set by the user (D).
During LITT, a damage zone of tissue achieving temperatures sufficient for ablation is represented by orange
pixels (E).
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Additional follow-up MRI studies are obtained 1–3 months postoperatively and then
at longer intervals depending on clinical status, pathology, and radiology findings.
3. Patient selection
3.1 Indications
The development of commercially available stereotactic LITT systems that allow
highly controlled delivery of laser light and real-time MRTI monitoring has enabled
the routine use of the LITT. Currently, LITT is a treatment option for a variety of
intracranial pathologies, including neoplasms (e.g., dural-based lesions, gliomas,
metastases), epileptogenic foci (e.g., medial temporal sclerosis, focal cortical dys-
plasia), radiation necrosis, and chronic pain syndromes. The application of LITT to
both newly diagnosed and recurrent gliomas has developed over the past decade;
reports from initial institutional experiences demonstrate that LITT can be safely
used for both supratentorial and infratentorial gliomas [28].
3.2 Criteria for patient selection
Identifying suitable candidates for LITT is important to ensure procedural safety
and to optimize target lesion ablation. We propose that LITT is a viable alternative
to open surgical resection in patients who meet the following criteria:
1. Lesion size of <3 cm diameter in any dimension. This size restriction reduces
the risk of damage to critical brain regions.
2. The surgeon can reasonably predict to achieve an extent of ablation of at least
80%. This threshold is generalized from previous studies of the extent of tumor
resection necessary to confer a significant survival benefit in open surgical
resection [8–11].
3. Lesions that are inaccessible via conventional open surgery (e.g., lesions
located adjacent to deep structures such as the basal ganglia, thalamus,
splenium, etc., in eloquent motor or speech areas or near critical neurovascular
structures).
4.Treatment refractory lesions (i.e., failure of previous craniotomy or radiation).
5. Patients with medical comorbidities, low preoperative functional status, or
history of previous craniotomy/radiation therapy who are unable to tolerate
prolonged anesthesia and blood loss or who are at high risk of surgical
morbidity and impaired wound healing. Of note, patients should still have a
preoperative functional status appropriate for a minimally invasive surgical
procedure under anesthesia; in our institutional experience, patients are
eligible if they have a Karnofsky Performance Score (KPS) of at least 70.
Therefore, LITT offers a minimally invasive cytoreductive therapy for patients
with surgically inaccessible or treatment refractory tumors who would not benefit
more from open surgical resection.
3.3 Illustrative case series
Here we present three cases of GBM tumors treated with LITT at our institution
(University of Miami, Miller School of Medicine). Case 1 illustrates the use of LITT
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for recurrent GBM. Case 2 demonstrates the use of LITT in treating primary GBM
and the utility of performing stereotactic needle biopsy during the same operative
setting to yield diagnostic information. In Case 3, we provide an example of subtotal
ablation of a recurrent GBM tumor.
3.3.1 Case 1
A 55-year-old gentleman with a 1-year history of GBM presented with focal
nodular enhancement in the right temporal lobe on surveillance MRI. One year
prior, he underwent surgical resection followed by temozolomide chemotherapy
and radiation. Upon presentation to our surgical neuro-oncology service, the patient
was asymptomatic; neurological exam was non-focal. Because of the surgeon’s
judgment that LITT would be able to achieve gross total ablation, the small size of
the lesion, and the patient’s history of treatment failure with surgical resection and
chemoradiation, the patient was consented for LITT. After the stereotactic place-
ment of the Visualase laser probe and confirmation of its location on intraoperative
MRI imaging (Figure 3A), LITT was performed according to the following treat-
ment parameters:
Figure 3.
A 55-year-old gentleman presenting with asymptomatic GBM recurrence. Intraoperative T2-weighted sagittal
MRI showing stereotactic placement of laser probe at target lesion (A). Postoperative day 1 of T1-weighted
axial MRI with contrast demonstrates gross total lesion ablation; hyperintense signal most likely represents blood
products (B) instead of residual tumor, as the same region does not enhance on T2-weighted MRI (C). At 22-
months follow-up,T1-weighted axial MRI imaging with contrast showed the patient was recurrence-free (D).
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1. Test dose at 4 W for 7 seconds. Concurrent real-time MRI thermometry data
confirmed total coverage of the target lesion.
2. Ablation dose at 10 W laser power for 3 minutes. Because MRI thermometry
data confirmed target area ablation and ablation temperature threshold was
reached (without reaching the maximum temperature threshold in off-target
zones), the treatment was considered complete.
T1-weighted MRI on postoperative day 1 showed gross total (100%) lesion
ablation (Figure 3B and C). The hyperintense signal in the tumor region
represented blood products. On follow-up, the patient remained recurrence-free for
over 2 years (26 months) (Figure 3D). The patient’s family reported his death
3 months following tumor recurrence.
3.3.2 Case 2
A 60-year-old gentleman with progressive gait instability and confusion for
2 weeks and worsening headache for 2 days presented to the emergency depart-
ment. MRI demonstrated a deep-seated left mesial temporal lobe lesion
(Figure 4A). Due to the location of the lesion and progression of his symptoms, the
patient was consented for stereotactic needle biopsy and LITT. In the operating
room, a trajectory for the stereotactic biopsy needle and laser probe was planned,
taking care to avoid critical cortical structures, ventricles, tentorium, arteries, and
veins, targeting the center of the lesion volume (Figure 4B). To perform stereotac-
tic needle biopsy, a preoperative and intraoperative computed-tomography scan
was obtained using an O-Arm (Medtronic) to register and confirm intralesional
biopsy. Two frozen cores of tissue were sent for pathological analysis, which
confirmed the presence of necrotic brain tissue. Following biopsy, the laser probe
was targeted to the lesion using neuronavigation with preoperative MRI registra-
tion. Follow-up T1-weighted MRI with contrast demonstrated gross total (100%)
ablation (Figure 4C). At 1.4-year follow-up, the patient remains recurrence-free.
3.3.3 Case 3
A 58-year-old female with history of GBM initially diagnosed 2 years prior
presented with focal recurrence in the left frontoparietal lobe on MRI imaging. The
recurrence had recently been treated with stereotactic radiosurgery, after which the
patient noticed new-onset right-hand weakness that did not improve with steroids.
Figure 4.
A 60-year-old gentleman found to have a new, deep-seated lesion on T1-weighted coronal MRI with contrast
suspicious for glioma (A). Intraoperative T2-weighted sagittal MRI shows stereotactic positioning of the laser
probe to access the lesion while avoiding critical brain structures (B). Postoperative T1-weighted sagittal MRI
with contrast demonstrates gross total ablation of the lesion (C).
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Neurological exam was positive for 4/5 strength in the right hand, but was other-
wise non-focal. MRI studies re-demonstrated the recurrence and extensive sur-
rounding edema (Figure 5A, B). Because the lesion was small (2.0 cm maximum
diameter) and failed both prior surgical resection and radiosurgery, the patient was
consented for LITT. The patient was induced under general anesthesia, and a laser
probe entry site and trajectory angle to the target lesion were planned using preop-
erative MRI imaging and Stealth neuronavigation (Medtronic, Inc.). The Visualase
thermal therapy system laser probe was inserted stereotactically along the planned
trajectory as described above (Figure 5C). The ablation procedure began with a test
dose of laser energy at 3 W (20% of maximum power) for 3 minutes. Concurrent
real-time MRI thermometry data was used to confirm target lesion coverage by the
developing ablation zone. Next laser power output was increased to 7.5 W (50%
maximum power) for 3 minutes, with successive 3-minute doses at 3 W stepwise
increases in power. Once target area coverage was maximized and ablation temper-
ature threshold reached (without reaching the maximum temperature threshold in
off-target zones), the laser power was increased to 90%maximum power output for
maximal ablation in 3-minute intervals. The final ablation zone was confirmed with
MRI thermometry.
There were no complications. The patient was discharged the following day on
a course of dexamethasone with steroid taper over 2 weeks. T1-weighted MRI
with contrast on postoperative day 1 showed subtotal ablation of 70% of the
pre-treatment volume (Figure 5D). Follow-up MRI imaging showed tumor
recurrence at 9-week post-LITT (Figure 5E). The patient died 10 months following
the procedure.
We present this case to illustrate how a subtotal ablation <80% may not be
sufficient to confer a clinical benefit.
Figure 5.
A 58-year-old female with left frontoparietal ring-enhancing lesion T1-weighted axial MRI with contrast
suspicious for tumor recurrence (A) with surrounding peripheral edema on T2-weighted FLAIR sequence
(B). Intraoperative sagittal T2-weighted MRI showing correct positioning of the laser probe to the lesion
(C). Postoperative day 1 of axial T1-weighted MRI (D) demonstrates subtotal (70%) thermal ablation of the
lesion. Follow-up T1-weighted MRI with contrast approximately 9-week post-LITT demonstrates tumor
progression (E).
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4. Clinical outcomes
The first case series reporting the use of LITT in gliomas were published in 1990
by Sugiyama et al., which described the successful total ablation of five deep-seated
gliomas [37]. The advent of MRI thermography and the Visualase and NeuroBlate
systems enabled institutional centers to publish data on larger case series over the
past decade. These initial experiences provide valuable evidence supporting the
safety and efficacy of LITT in select patient. In Table 1 we present a comprehensive
review of the literature of studies evaluating clinical outcomes in patients treated
with LITT for either newly diagnosed or recurrent GBM tumors. To accurately
represent the current use of LITT, only studies that included the use of real-time
MR thermography are included in our review.
Abbreviations: M, male; F, female; NR, not reported; LITT, laser interstitial
thermal therapy; STA, subtotal ablation; SupA, supra-ablation
5. Discussion
5.1 Current role of LITT in neurosurgery
The use of laser-based ablation technology in neurosurgery began with the
treatment of movement disorders, chronic pain syndromes, and epilepsy. Techno-
logical advances over the past two decades in laser interstitial thermal therapy
delivery platforms and real-time MR thermal imaging of tissue ablation dynamics
have made LITT a viable minimally invasive therapy for a variety of intracranial
and spinal lesions, including metastases, epileptogenic foci, radiation necrosis,
dural-based lesions, and gliomas.
The advantage of LITT in treating gliomas includes:
1. Achieving cytoreduction in poor open surgical candidates: because laser light is
delivered through a 1–3-mm diameter laser probe inserted through a single
burr hole and dural opening, LITT reduces the risk of morbidity associated
with craniotomy for surgical resection. This is especially relevant in GBM
patients as the risk of neurological morbidity and poor wound healing or
infection increases with repeat craniotomies and radiation therapy. The ability
to tightly control the ablation zone using real-time MR thermography means
that LITT is well suited for treatment of lesions in deep-seated locations or near
critical structures.
2. Shorter procedure time and quicker recovery: the small incision required may
result in fewer wound-healing complications, particularly in patients with
impaired wound healing due to prior craniotomies or radiation therapy. Finally,
a minimally invasive approach enables a quicker recovery and transition to
continue chemotherapy or initiate another adjuvant therapy [26, 39].
3. The use of non-ionizing radiation: unlike ionizing radiation therapy, LITT
thermal therapy can be used repeatedly without the risk of radiation necrosis
[9]. Moreover, LITT can be used as a salvage therapy in treatment refractory
tumors and may avoid increased risk of secondary malignancy-associated
ionizing radiation [18].
4.Treatment of lesions that are inaccessible via open surgery: gliomas located in
deep or eloquent regions of the brain (e.g., insula, thalamus, corpus callosum)
10
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Reference #
Cases
Newly-
diagnosed
or
recurrent
GBM
lesions
Age, Gender Location of lesion LITT
system
used,
Extent of
ablation
Mean/median
Recurrence-
free survival;
Overall
survival
Schwartzmaier
et al. 2005 [29]
2 Recurrent 47 M
67 M
1 Temporal
1 Parietooccipital
1064 nm
laser, STA
1 recurrence;
13-16 months
Schwartzmaier
et al. 2006 [30]
16 Recurrent Median age 62,
range 44-69, 10
men, 6 women
3 Frontal
1 Frontoparietal
1 Frontotemporal
1 Temporal
1 Parietal
3 Parietooccipital
1 Corpus callosum
1 Parasagittal
1064 nm
laser; NR
6.9 months; NR
Carpentier et
al. 2012 [26]
4 Recurrent 40-58
years, 3 men,
1 woman
1 temporo-polar
1 corpus callosum
1 frontal
1 temporal
Visualase;
SupA of
1 mm
diameter or
more
1.25 months; 10
months
Jethwa et al
2012 [19]
4 Newly-
diagnosed
Media n 60
years, range
56-81
right frontal right
frontal left
temporal right
midbrain
Visualase,
NR
NR; NR
Hawasli et al.,
2013 [31]
6 Newly-
diagnosed
Media n 50
years, range
34-78,
6 men,
2 women
thalamus
left thalamus basal
ganglia left
thalamus right
corpus callosum
thalamus
Neuroblate;
median
90.3%
ablation
Recurrence in 3
of 6 patients
at median 3.2
months (range
2.5-15 months);
3 of 6 patients
alive at last
follow-up, 3 of
6 patients died
at median 1.7
months
Sloan et al.
2013 [27]
10 Recurrent Media n 54
years, range
34-69.
8 men, 2
women
2 temporal
1 temporoparietal
1 temporooccipital
3 parietal
3 frontal
NR 10.5 months;
Mohammadi et
al. 2014 [32]
24 Recurrent
(14) and
new (10)
lesions
Media n age 56
(range 19-79),
38%
female
15 tumors in
frontal lobe,
7 in thalamic
region, 5 parietal,
5 temporal,
2 insular,
1 corpus callosum.
Neuroblate;
Median
ablation
volume at
yellow line:
98%, at blue
line: 91%
(includes
non-GBM
tumors
included in
study)
5.1 months;
68% survival at
1 year
Thomas et al.
2016 [33]
21 Recurrent
(13) and
new (8)
lesions
Mean age 49
years
8 in eloquent
regions (62%):
3 in motor cortex,
3 in speech,
1 temporal,
2 splenium,
2 cingulate,
2 insular
NeuroBlate;
NR
5 months;
7 months
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may increase open surgical risk to a degree that patients only receive stereotactic
needle biopsy and adjuvant chemoradiation, thus losing the survival benefit
associated with aggressive cytoreduction. Because LITT is delivered through a
thin laser probe, lesions that are typically considered “surgically inaccessible”
can now be treated with reduced risk of neurological morbidity [39].
The use of LITT for gliomas was initially limited to treating recurrences that
failed conventional first-line therapies (i.e., surgical resection and adjuvant
chemoradiation). Recently, LITT has been applied as a primary treatment for
newly-diagnosed gliomas. Preliminary institutional experiences report local control
and overall survival times of several months—over 1 year.
Patient selection is of critical importance in ensuring safe and effective use of
LITT. To summarize, lesions should be <3 cm in diameter, in a region that can be
accessed via a linear laser catheter trajectory without injury to critical structures and
in patients who are able to tolerate a minimally invasive surgical procedure under
anesthesia. In addition, the lesion should have identifiable margins such that at
least 80% of the target area can be feasibly ablated with a roughly spherical ablation
zone.
5.2 Limitations of LITT
The increasing use of LITT has revealed it to be an overall safe, well-tolerated
procedure. The most common adverse events associated with the procedure include:
1. Intracranial hemorrhage: despite the use of neuronavigation and stereotaxy for
trajectory planning, the laser probe may be malpositioned, resulting in injury
to vessels and bleeding [40]. Estimates of overall rates of accurate implantation
range from 85.7 to over 95%, with only three reported cases of resulting
intracranial hemorrhage resulting from malpositioning [19, 40]. The risk of
Reference #
Cases
Newly-
diagnosed
or
recurrent
GBM
lesions
Age, Gender Location of lesion LITT
system
used,
Extent of
ablation
Mean/median
Recurrence-
free survival;
Overall
survival
Shah et al.,
2016 [34]
7 Newly-
diagnosed
Mean age 59,
3 male,
4 female
1 splenium
1 orbitofrontal
1 parieto- occipital
1 post. Cingulate
1. precuneus
1 Genu
Visualase;
mean 98.5%
14.3 months;
6 of 7 patients
alive at last
follow-up,
1 death at
14 months
Schroeder et al.
2014 [35]
5 Newly-
diagnosed
Mean age 47 94% 11.5 months;
NR
Kamath et al.
2019 [36]
54 Recurrent
(41) and
Newly-
diagnosed
(17)
Mean age 59
years
14 frontal
8 temporal
9 parietal
1 occipital
4 pareito-occipital
4 temporo-parietal
8 corpus callosum
2 insular
8 thalamic
Neuroblate;
93.2%
(yellow
boundary),
88.0% (blue
boundary)
6.6 months;
11.5 months
Abbreviations: M, male; F, female; NR, not reported; LITT, laser interstitial thermal therapy; STA, subtotal ablation;
SupA, supra-ablation.
Table 1.
Literature review of case series describing LITT for GBM (adapted from: [9, 38]).
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hemorrhage may be reduced by obtaining a computed-tomography
angiography (CTA) showing the location of critical vessels to avoid during
laser trajectory planning.
2. Transient neurological deficit: neurological deficits such as weakness,
hemianopsia, seizures, and dysphagia are often attributed to direct thermal
injury to functional brain areas or cerebral edema. Estimates of transient
neurological deficits have been reported to occur in 13–15% of patients [19, 40].
Permanent neurological morbidity is less common (5.6% of cases according to a
recent literature review) [40]. Cerebral edema is frequently observed in the
immediate postoperative period following LITT. A recent volumetric and time-
course analysis found that edema volume has been shown to increase on
average 41.5% immediately postoperatively, followed by a gradual decline
resulting on average an 80.9% decrease in preoperative edema volume [28].
Although cerebral edema is common, it is unlikely to cause permanent
neurological deficits and may be controlled with a course of steroids. Treatment
of large (>3cm) lesions, use of multiple laser probes, or use of multiple laser
trajectories is associated with a higher risk of significant cerebral edema [41].
Less common (<5% of all cases) complications include permanent neurological
deficit, infection (e.g., ventriculitis, meningitis, or brain abscess), deep venous
thrombosis, diabetes insipidus, hyponatremia, and intracranial hypertension. There
is one reported case of gliosarcoma tumor seeding along the laser probe tract [27].
Finally, there are only two recorded deaths attributed to LITT in the literature, from
postoperative meningitis and intracranial hemorrhage [32].
Our discussion of patient selection also reveals specific limitations of LITT.
Multiple reviews cite a lesion size limit of 3 cm to reduce the chance of intracranial
hypertension secondary to edema [18, 31]. As discussed previously, preoperative
functional status, lesion accessibility by a laser trajectory, and anticipated extent of
ablation are also factors that limit the use of LITT to particular lesions.
5.3 Future directions
In discussing complication rates, it is important to emphasize that LITT is a
novel procedure, and so practitioners and institutions operate with a learning curve
[18]. Recently, more institutional case series have proposed modifications to
improve safety, for example, staging the treatment of larger (>3 cm) lesions to over
multiple procedures to avoid morbidity or employing algorithms to optimize laser
trajectory planning [42].
Along with further improvements in procedural safety, the future of LITT may
lie in combination therapies to enhance tumor control and overall survival. Previous
studies have shown that LITT induces a temporary increase in blood-brain barrier
(BBB) permeability, which may offer a window of opportunity to deliver adjuvant
chemotherapy more effectively [42, 43]. Another line of investigation is the use
of gold nanoparticles, which may enhance tissue energy absorption and increase
ablation efficacy [45].
Finally, future investigations will require prospective and randomized-controlled
trials to evaluate the clinical outcomes of LITT compared to other therapies.
6. Conclusion
LITT is a novel adjuvant therapy for treatment of a wide variety of intracranial
pathologies. In this chapter we review the evidence supporting the safety and
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efficacy of LITT as a primary or adjuvant treatment for glioblastoma. Thus far,
LITT is a safe, minimally invasive approach to cytoreduction in patients with
gliomas that are poor open surgical candidates.
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